ARCHIVES

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Grants: BSA Subcommittee Recommends Review Of SPORE Program In Year 2000

June 26, 1998

NCI Bid For New Clinical Review Panel Rejects; But Invites Researchers To ‘Submit Best Ideas’

March 8, 1991

What the Physician Pay Report Won’t Tell You

April 11, 2014

New Breast Cancer Trials to Include Pre Vs. Post Operative Chemotherapy, CSF Pilot Studies

August 5, 1988

Signet Cell A Rising Trend In Patients Under Age 40

November 25, 2011

USC Cancer Center Plans Expansion, Gets New Name

January 27, 1989